SynopsisRetigabine is a highly pure, synthetic, and biologically active compound. The global Retigabine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030. N.....
SynopsisAntipain Dihydrochloride is a protease inhibitor isolated from actinomycetes. The global Antipain Dihydrochloride market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period .....
SynopsisKinetin is a plant hormone that promotes cell division. The global Kinetin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030. North American market .....
Synopsis1-Naphthylacetic acid is a synthetic plant hormone in the auxin family and is an ingredient in many commercial plant rooting horticultural products. The global 1-Naphthylacetic Acid (NAA) market was valued at US$ million in 2023 and is anticipated to rea.....
SynopsisTraumatic Acid is a product of the hydroperoxide lyase pathway in plants. Potential as a wound healing agent that stimulates cell division near a wound site to form a protective callus. The global Traumatic Acid market was valued at US$ million in 2023 a.....
SynopsisEbselen is an organoselenium compound that displays anti-inflammatory and antioxidant properties. The global Ebselen market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast peri.....
SynopsisDarapladib is a reversible lipoprotein-associated phospholipase A2 inhibitor. The global Darapladib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
SynopsisAnacetrapib is a CETP inhibitor being developed to treat hypercholesterolemia and prevent cardiovascular disease. The global Anacetrapib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % duri.....
SynopsisDalcetrapib is a CETP inhibitor.Inhibition of CETP is a target to increase HDL-cholesterol and potentially reduce atherosclerosis. The global Dalcetrapib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing.....
SynopsisEvacetrapib is a cholesterol ester transfer protein inhibitor that exhibits anti-atherosclerotic activity. The global Evacetrapib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the .....
